异基因造血干细胞移植后T大颗粒淋巴细胞增多的临床特征与危险因素分析
该回顾性研究纳入359例接受allo-HSCT的患者,其中17例发生T-LGL。移植后1、2、3年T-LGL累积发生率分别为3.64%、4.50%和4.84%。CMV再激活、EBV血症和aGVHD与T-LGL发生相关,良性血液病、单倍型移植和无关供者移植为独立预测因素。恶性疾病患者发生T-LGL后预后良好。
要点
- allo-HSCT后T-LGL累积发生率1年3.64%、2年4.50%、3年4.84%。
- CMV再激活、EBV血症和aGVHD与T-LGL发生相关。
- 良性血液病、单倍型移植和无关供者移植是T-LGL独立预测因素。
核心结论
- 恶性疾病患者移植后T-LGL可能是一个较为持久的良性临床过程。
研究设计与样本
- 回顾性分析2013年6月至2020年2月接受allo-HSCT的359例患者连续性资料,中位年龄38(7~65)岁。
主要发现
- 移植后1、2、3年T-LGL累积发生率分别为3.64%(95%CI 1.09%~6.19%)、4.50%(95%CI 1.36%~7.64%)和4.84%(95%CI 1.10%~8.76%)。
- CMV再激活(P=0.013)、EBV血症(P=0.034)以及aGVHD(P=0.027)均与T-LGL发生有关。
- 多因素分析显示良性血液病[P=0.027,OR=3.36(95%CI 1.15~9.89)]、单倍型移植[P=0.030,OR=4.67(95%CI 1.16~18.75)]、无关供者移植[P=0.041,OR=5.49(95%CI 1.10~28.16)]为独立预测因素。
- 两组3年OS(100.0%对78.6%,P=0.04)、DFS(100.0%对70.0%,P=0.01)、CIR(0对16.1%,P<0.01)和NRM(0对12.6%,P=0.02)差异均有统计学意义。
- 亚组分析显示恶性疾病患者发生T-LGL后NRM、DFS和CIR差异有统计学意义(P值均<0.05),良性疾病患者发生T-LGL对预后无明显影响。
关键数值与推荐
- T-LGL累积发生率:1年3.64%(95%CI 1.09%~6.19%)、2年4.50%(95%CI 1.36%~7.64%)、3年4.84%(95%CI 1.10%~8.76%)。
- 独立预测因素:良性血液病OR=3.36(95%CI 1.15~9.89,P=0.027)、单倍型移植OR=4.67(95%CI 1.16~18.75,P=0.030)、无关供者移植OR=5.49(95%CI 1.10~28.16,P=0.041)。
临床怎么用
- allo-HSCT后发生T-LGL在恶性疾病患者中提示预后良好,可能无需过度干预。
- 对于良性血液病患者,移植后发生T-LGL对预后无明显影响。
局限性
- 本研究为单中心回顾性分析,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinical characteristics, related factors, and prognostic effect of patients with T cell large granular lymphocytosis following allo-HSCT. Methods: Consecutive patients with T-LGL following allo-HSCT who visited our center from June 2013 to February 2020 were studied retrospectively. We compared patients undergoing allo-HSCT during this period. The clinical characteristics, related factors, cumulative incidence of patients with T-LGL and rates of overall survival (OS) , disease free survival (DFS) , relapse, and non-relapse mortality (NRM) were analyzed. Results: Total 359 patients were enrolled, including 17 with T-LGL and 342 without T-LGL following allo-HSCT. The median follow-up duration was 38 (3-92) month. The cumulative incidence at 1-, 2- and 3-years of T-LGL was 3.64% (95%CI 1.09%-6.19%) , 4.50% (95%CI 1.36%-7.64%) , and 4.84% (95%CI 1.10%-8.76%) , respectively. CMV reactivation (P=0.013) , EB viremia (P=0.034) , and aGVHD (P=0.027) were associated with the development of T-LGL following allo-HSCT. Multivariate analysis showed that benign hematologic diseases[P=0.027, OR=3.36 (95%CI 1.15-9.89) ] and haploidentical hematopoietic stem cell transplantation[P=0.030, OR=4.67 (95%CI 1.16-18.75) ], unrelated donor transplantation[P=0.041, OR=5.49 (95%CI 1.10-28.16) ] were independent predictive factors of T-LGL following allo-HSCT. There was a significant difference in the 3-year OS (100.0% vs. 78.6%, P=0.04) , DFS (100.0% vs. 70.0%, P=0.01) , and NRM (0 vs. 12.6%, P=0.02) between the 2 cohorts. Subgroup analysis showed that malignant diseases recipients who developed T-LGL had better outcomes after allo-HSCT, and there was a significant difference in the NRM (P=0.042) , DFS (P=0.013) , and cumulative relapse rate (P=0.028) between the 2 cohorts. In contrast, the appearance of T-LGL after allo-HSCT in patients with benign diseases had no significant effect on the prognosis. Conclusions: T-LGL was a durable and clinically benign phenomenon occurring in allo-HSCT recipients with malignant diseases. Factors associated with immune reconstitution and T-cell regulatory mechanisms might be major predictors of T-LGL following allo-HSCT. 目的: 探讨异基因造血干细胞移植(allo-HSCT)后发生T大颗粒淋巴细胞增多(T-LGL)患者的临床特征、相关因素以及对预后的影响。 方法: 回顾性分析2013年6月至2020年2月接受allo-HSCT的359例患者连续性资料,男216例,女143例,中位年龄为38(7~65)岁。分析T-LGL的临床特征、累积发生率,比较发生与未发生T-LGL患者的总生存(OS)率、无病生存(DFS)率、累积复发率(CIR)及非复发死亡率(NRM)的差异,并研究影响移植后发生T-LGL的相关因素。 结果: 共入组359例患者,T-LGL组17例,非LGL组342例,中位随访38(3~92)个月,移植后1、2、3年T-LGL累积发生率分别为3.64%(95%CI 1.09%~6.19%)、4.50%(95%CI 1.36%~7.64%)和4.84%(95%CI 1.10%~8.76%);移植受者CMV再激活(P=0.013)、EBV血症(P=0.034)以及急性移植物抗宿主病(P=0.027)均与T-LGL发生有关,且多因素分析显示,良性血液病[P=0.027,OR=3.36(95%CI 1.15~9.89)]、单倍型移植[P=0.030,OR=4.67(95%CI 1.16~18.75)]、无关供者移植[P=0.041,OR=5.49(95%CI 1.10~28.16)]为移植后发生T-LGL的独立预测因素。两组患者移植后3年OS、DFS率、CIR以及NRM差异均有统计学意义[OS:100.0%对78.6%(95%CI 74.1%~83.1%),P=0.04;DFS:100.0%对70.0%(95%CI 64.9%~75.1%),P=0.01;CIR:0对16.1%(95%CI 11.8%~22.4%),P<0.01;NRM:0对12.6%(95%CI 12.5%~12.6%),P=0.02]。亚组分析结果显示,恶性疾病患者移植后发生T-LGL者预后良好,NRM、DFS率以及CIR差异均有统计学意义(P值均<0.05),而良性疾病患者移植后发生T-LGL对预后无明显影响。 结论: 恶性疾病患者移植后T-LGL可能是一个较为持久的良性临床过程,与免疫重建和T细胞调节机制相关的因素可作为移植后T-LGL发生的主要预测因素。.
引用
- Zhao F, Shi YY, Zhang GX, et al. [Clinical features and risk factors analyses of patients with T cell large granular lymphocytosis following allo-HSCT]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32942815. doi:10.3760/cma.j.issn.0253-2727.2020.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。